Handelsbanken Fonder AB Invests $2.87 Million in Revvity, Inc. (NYSE:RVTY)

Handelsbanken Fonder AB bought a new position in shares of Revvity, Inc. (NYSE:RVTY) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 26,260 shares of the company’s stock, valued at approximately $2,870,000.

Several other hedge funds have also modified their holdings of the company. Vanguard Group Inc. purchased a new stake in shares of Revvity during the 3rd quarter worth about $1,579,487,000. Ceredex Value Advisors LLC purchased a new stake in shares of Revvity during the 4th quarter worth about $108,353,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Revvity during the 4th quarter worth about $33,568,000. Boston Trust Walden Corp purchased a new stake in shares of Revvity during the 4th quarter worth about $25,154,000. Finally, KBC Group NV purchased a new stake in shares of Revvity during the 3rd quarter worth about $25,301,000. 86.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Raymond James increased their price objective on shares of Revvity from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. KeyCorp raised their price target on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. UBS Group downgraded shares of Revvity from a “buy” rating to a “neutral” rating and raised their price target for the stock from $105.00 to $125.00 in a report on Tuesday, January 16th. Evercore ISI upgraded shares of Revvity from an “in-line” rating to an “outperform” rating and lifted their target price for the company from $88.00 to $125.00 in a report on Thursday, January 4th. Finally, Stifel Nicolaus lifted their target price on shares of Revvity from $95.00 to $110.00 and gave the company a “hold” rating in a report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Revvity currently has an average rating of “Moderate Buy” and a consensus price target of $118.91.

Insider Buying and Selling at Revvity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the transaction, the insider now owns 92,801 shares of the company’s stock, valued at approximately $9,677,288.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.60% of the stock is currently owned by corporate insiders.

Revvity Stock Performance

Shares of RVTY stock opened at $101.51 on Friday. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40. Revvity, Inc. has a 52 week low of $79.50 and a 52 week high of $132.54. The stock has a market capitalization of $12.54 billion, a PE ratio of 18.46, a P/E/G ratio of 2.67 and a beta of 1.09. The firm has a 50 day moving average of $104.66 and a two-hundred day moving average of $101.46.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Thursday, February 1st. The company reported $1.25 EPS for the quarter, beating the consensus estimate of $1.15 by $0.10. Revvity had a net margin of 25.20% and a return on equity of 7.41%. The company had revenue of $695.90 million during the quarter. On average, research analysts predict that Revvity, Inc. will post 4.65 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.28%. Revvity’s dividend payout ratio is presently 5.09%.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.